MiMedx Group (NASDAQ:MDXG) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a sell rating in a report published on Saturday.

MDXG has been the subject of several other reports. Citizens Jmp lowered their price objective on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Weiss Ratings downgraded MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Finally, Craig Hallum decreased their price target on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Stock Up 3.4%

MiMedx Group stock opened at $4.27 on Friday. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. The firm has a market cap of $622.40 million, a price-to-earnings ratio of 106.78 and a beta of 1.45. The business’s 50-day moving average price is $3.94 and its 200 day moving average price is $4.22. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.97.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $64.36 million for the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. As a group, sell-side analysts anticipate that MiMedx Group will post -0.09 earnings per share for the current year.

Institutional Trading of MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sunbelt Securities Inc. acquired a new stake in shares of MiMedx Group during the first quarter worth about $42,000. Kemnay Advisory Services Inc. acquired a new position in MiMedx Group in the 4th quarter valued at about $48,000. Williams & Novak LLC acquired a new position in MiMedx Group in the 2nd quarter valued at about $53,000. Y Intercept Hong Kong Ltd acquired a new position in MiMedx Group in the 1st quarter valued at about $65,000. Finally, Headlands Technologies LLC purchased a new stake in MiMedx Group during the 2nd quarter valued at approximately $72,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.